Eli Lilly & Co.'s blockbuster weight-loss and diabetes drugs are no longer considered to be in shortage in the US, ...

After nearly two years, federal regulators announced the shortage of the active ingredient in Mounjaro and Zepbound has been ...

Eli Lilly said Wednesday it will invest $4.5 billion to build an advanced pharmaceutical drug manufacturing and development ...

A woman who started taking a popular weight loss medication through a clinical trial had to look for alternatives when her ...

In a high-profile showdown Tuesday with Sen. Bernie Sanders’ Senate health committee, Novo Nordisk CEO Lars Fruergaard ...

Pharma stocks have been on quite a nice run over the past year. A number of new catalysts have revitalized this sector, which ...

If anything, the four-week supply of the 2.5 mg Zepbound single-dose vial at $399 (self-pay) is not too far from HIMS' compounded GLP-1 injectables from $199 monthly (based on a 12-month plan).

She also said that “Lilly has led the way on access and affordability,” having launched “Zepbound at a list price 20% lower than our competitor, and last month we launched single-dose vials ...

Both Zepbound and Mounjaro have the same active ... based in Indianapolis. “They are single-dose vials, and so I think when people think of big vials of insulin, they are probably thinking ...

as evidenced by Eli Lilly’s recent decision to significantly reduce the cost of Zepbound for cash-paying patients who are willing to self-administer single-dose vials using a needle and syringe ...